Pat Whitworth, MD, FACS
Breast Surgical Oncology Specialist, Director of the Nashville Breast Center
| 0:34 |
Clinical Need–takeaways from DCIS randomized landmark trials, RTOG, NCCN |
Troy Bremer, PhD
Founder & Chief Scientific Officer of PreludeDx
| 5:08 |
Genomic Solution—DCISionRT |
| 8:56 |
Who will recur despite BCS+RT? |
| 9:42 |
Pathway for residual recurrence risk |
| 10:52 |
About Residual Risk Subtype (RRt) |
Chirag Shah, MD
Co-Director of Comprehensive Breast Program and Director of Clinical Research in the Department of Radiation Oncology at the Cleveland Clinic
| 11:15 |
Validation data of DCISionRT+RRt |
| 14:20 |
Stratification for RT benefit and NNT |
| 18:20 |
RRt clinpath subpopulations |
Pat Whitworth, MD, FACS
Breast Surgical Oncology Specialist, Director of the Nashville Breast Center
| 19:05 |
Validation supporting true low risk and RT benefit groups |
| 20:43 |
Age and grade Subpopulation analysis |
| 23:40 |
Individualized patient care |
Troy Bremer, PhD
Founder & Chief Scientific Officer of PreludeDx
| 24:00 |
Summary: Supportive evidence |
| 26:22 |
Real-world Case Studies |
Panel Q and A Discussion
| 33:36 |
Addressing microcalcifications in study cohort |
| 34:19 |
Local Recurrence rate vs metastatic rate in study cohort |
| 35:06 |
Margins status and DS in study cohort and treatment implications |
| 37:33 |
Hormone Receptor status in study cohort and treatment implications |
| 41:55 |
Overcoming nuclear grade subjectivity |
| 43:36 |
Management of patients meeting RTOG criteria |
| 44:52 |
RT modalities |
| 45:42 |
Implementing into clinical practice |
| 48:15 |
Specimen type for testing |
| 49:30 |
RRt vs Decision Score |
| 50:25 |
RRt treatment implications |
| 50:25 |
Closing statements from KOLs |
